Activatable Cytokine Constructs Reduce Systemic Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cytokine therapies, such as interferon and interleukin treatments, suffer from systemic toxicities and limited specificity, leading to dose-dependent side effects and reduced therapeutic efficacy due to non-targeted delivery.
Innovation Solution
Development of activatable cytokine constructs (ACCs) comprising monomers with peptide masks, cleavable moieties, and dimerization domains, which are activated by proteases overexpressed in diseased tissues, allowing targeted cytokine activity in tumor microenvironments while minimizing activity in healthy tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic interferon or interleukin therapy is administered, then therapeutic efficacy against viral infections and cancers is improved, but dose-dependent systemic toxicities worsen
Solution Approach 1:
The cytokine construct is divided into separate functional domains: a cytokine domain, a cleavable linker domain, and a dimerization domain. This segmentation allows the cytokine to be delivered systemically in an inactive or partially active state, then activated locally at the target site through protease-mediated cleavage, thereby achieving therapeutic efficacy while reducing systemic toxicities
Solution Approach 2:
The construct incorporates a protease cleavage site with specific sequence characteristics that match the protease profile of diseased tissues (e.g., tumors or viral infection sites). This ensures that cytokine activation occurs preferentially at the disease site where the protease is overexpressed, creating local quality differences between healthy and diseased tissues
2Reliability
If cytokine dosage is increased to overcome resistance or enhance efficacy, then therapeutic effect is improved, but side effects worsen
Solution Approach 1:
The construct is designed with a dimerization domain that promotes self-assembly into higher-order structures. This preliminary structural organization occurs during circulation, preparing the cytokine for activated state upon protease cleavage. The dimerization enhances potency per molecule, allowing lower dosages to achieve the same therapeutic effect, thereby reducing side effects
3Area of stationary object
If cytokine therapy is administered systemically, then broad coverage of target tissues is achieved, but specificity to diseased sites deteriorates
Solution Approach 1:
A protease cleavage site serves as an intermediary element between the cytokine domain and dimerization domain. This intermediary is designed with sequence characteristics that make it a preferred substrate for proteases overexpressed in diseased tissues. The intermediary enables the cytokine to circulate systemically with broad coverage while ensuring that activation (and thus effective targeting) occurs specifically at diseased sites where the protease is present
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ACCs reduce systemic toxicity, enable higher dosages, and increase the therapeutic window by localizing cytokine activity to disease sites, thereby enhancing treatment efficacy and reducing side effects.
Implementation Method 1
the CM1, the CM2, and the CM3 function as a substrate for a protease
Implementation Method 2
the DD1 and the DD2 bind to each other
Data Source
AI summary
Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.